Transpact Enterprises Limited
BSE: TRANSPACT · Medical Equipment & Supplies · sector
Key numbers
Last 12 months to Mar 2026, Standalone. "Sector median" = middle value of 15 companies in Medical Equipment & Supplies (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Other income was 0% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹100.50 on 2026-10-26: -57.2% from the 52-week high, +23.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| EBITDA | 0 | 0 | 0 |
| OPM % | 75.0% | 70.0% | 55.6% |
| Other income | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 |
| EPS (₹) | 0.13 | 0.13 | 0.10 |
Standalone figures where filed. Latest quarter Mar 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | – | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -0 | 0 | 0 | 0 |
| Net profit | -0 | -0 | -0 | 0 | 0 | 0 |
| EPS (₹) | -6.23 | -1.70 | – | 0.02 | 0.22 | 0.22 |
| Revenue growth | +153.3% | – | – | +125.0% | – | |
| Profit growth | – | – | – | +800.0% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -22.0% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -30.6% (2y) | -58.0% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 0 | 0 |
| Borrowings | 0 | – |
| Cash & equivalents | 0 | 0 |
| Total assets | 1 | 1 |
| Fixed assets | 0 | 0 |
| Capital work in progress | 0 | – |
| Investments | 0 | 0 |
| Receivables | 0 | – |
| Inventory | 0 | 0 |
| Payables | 0 | – |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -0 | 0 |
| Cash from investing | 0 | -0 |
| Cash from financing | 0 | -0 |
| Capex | 0 | 0 |
| Free cash flow | -0 | 0 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 2.0% | 59.5% |
| ROCE % | 0.8% | 55.4% |
| Debtor days | 0 | – |
| Inventory days | 55 | 0 |
| Payable days | 98 | – |
| Cash conversion cycle (days) | -43 | – |
| Working capital days | 1,090 | 935 |
Peers in Medical Equipment & Supplies
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| POLYMED | ₹14,631 cr | 46.4x | 4.7x | 10.7% | 12.7% | 22.8% | +18.9% | 0.24% |
| MOLBIO | ₹14,360 cr | – | – | – | – | – | – | – |
| TARSONS | ₹1,587 cr | 142.7x | 2.5x | 1.8% | 4.1% | 26.8% | +14.3% | – |
| LAXMIDENTL | ₹945 cr | 30.4x | 3.9x | 13.7% | 13.4% | 14.0% | – | – |
| FISCHER | ₹856 cr | 11.2x | 2.2x | -0.8% | 11.6% | 13.6% | – | 0.04% |
| HSIL | ₹740 cr | 36.9x | 6.5x | 21.8% | 24.1% | 10.0% | – | – |
| FABTECH | ₹543 cr | 8.8x | 1.3x | 11.6% | 13.6% | 10.9% | – | – |
| PREVEST | ₹455 cr | 14.7x | 4.0x | 29.9% | 36.9% | 34.1% | +12.9% | 0.26% |
| NURECA | ₹296 cr | 63.0x | 1.6x | 2.5% | 5.3% | 3.5% | +9.7% | – |
| TRANSPACT | ₹38 cr | 456.8x | 263.0x | 29.0% | 55.4% | 65.3% | -22.1% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Medical Equipment & Supplies |
| Sub-industry | Medical Equipment & Supplies |
| Symbol | TRANSPACT |
| BSE code | 542765 |
| ISIN | INE06YD01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.